The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
Open accessAbstract
NF-κB in defense and diseaseNF-κB comprises a family of inducible transcription factors that serve as important regulators of the host immune and inflammatory response.In addition, NF-κB is also involved in protecting cells from undergoing apoptosis in response to DNA damage or cytokine treatment.Stimulation of the NF-κB pathway is mediated by diverse signal transduction cascades.These signals activate the IκB kinases, IKKα and IKKβ, which phosphorylate inhibitory proteins known as IκB to result in their ubiquitination and degradation by the proteasome.The degradation of IκB results in the translocation of NF-κB from the cytoplasm to the nucleus where it activates the expression of specific cellular genes.As we better understand the regulation of the NF-κB pathway, the potential for inhibiting this pathway has received attention.Agents that inhibit this pathway, such as glucocorticoids and aspirin, can reduce the inflammatory response, while other agents such as dominant negative IκB proteins potentiate the effects of chemotherapy and radiation therapy in the treatment of cancer.Here, we discuss cellular genes and disease states associated with activation of the NF-κB pathway and consider therapeutic strategies to prevent the prolonged activation of the NF-κB pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB
Wang, C.-Y., Mayo, M. W., & Baldwin, A. S. (1996) · Science · doi:10.1126/science.274.5288.784 · Cited by 2,617
Suppression of TNF-α-Induced Apoptosis by NF-κB
Van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R., & Verma, I. M. (1996) · Science · doi:10.1126/science.274.5288.787 · Cited by 2,581
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Auphan, N., DiDonato, J. A., Rosette, C., Helmberg, A., & Karin, M. (1995) · Science · doi:10.1126/science.270.5234.286 · Cited by 2,390 · cited 2×
“The first mechanism is consistent with a role for glucocorticoids in inducing expression of IκBα to enhance the cytosolic retention of NF-κB (26, 27).”
BackgroundRole of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids
Scheinman, R. I., Cogswell, P. C., Lofquist, A. K., & Baldwin, A. S. (1995) · Science · doi:10.1126/science.270.5234.283 · Cited by 1,699
The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
Yin, M.-J., Yamamoto, Y., & Gaynor, R. B. (1998) · Nature · doi:10.1038/23948 · Cited by 1,590
Self-citationProteasome inhibitors: a novel class of potent and effective antitumor agents.
Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J. I., Destree, A. T., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., & Elliott, P. J. (1999) · PubMed · Cited by 1,477
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,231
Control of apoptosis by Rel/NF-κB transcription factors
Barkett, M., & Gilmore, T. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203238 · Cited by 1,204
Aberrant rel/nfkb genes and activity in human cancer
Rayet, B., & Gélinas, C. (1999) · Oncogene · doi:10.1038/sj.onc.1203221 · Cited by 1,110
Wang, C.-Y., Cusack, J. C., Liu, R., & Baldwin, A. S. (1999) · Nature Medicine · doi:10.1038/7410 · Cited by 988
NF-κB in neuronal plasticity and neurodegenerative disorders
Mattson, M. P., & Camandola, S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11916 · Cited by 877
Scheinman, R. I., Gualberto, A., Jewell, C. M., Cidlowski, J. A., & Baldwin, A. S. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.2.943 · Cited by 819
Hinz, M., Krappmann, D., Eichten, A., Heder, A., Scheidereit, C., & Strauss, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2690 · Cited by 788
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
NF-κB: pivotal mediator or innocent bystander in atherogenesis?
Collins, T., & Cybulsky, M. I. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10373 · Cited by 727
Vane, J. (1994) · Nature · doi:10.1038/367215a0 · Cited by 699
Wang, C.-Y., Guttridge, D. C., Mayo, M. W., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5923 · Cited by 590
Tsai, S., Lin‐Shiau, S., & Lin, J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702357 · Cited by 511
Holmes-McNary, M. Q., & Baldwin, A. S. (2000) · PubMed · doi:10.17615/wdcc-wb89 · Cited by 498
Sulindac Inhibits Activation of the NF-κB Pathway
Yamamoto, Y., Yin, M.-J., Lin, K.-M., & Gaynor, R. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.27307 · Cited by 494
Self-citationIEX -1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell Survival
Wu, M. X., Ao, Z., Prasad, K. V. S., Wu, R., & Schlossman, S. F. (1998) · Science · doi:10.1126/science.281.5379.998 · Cited by 413
Grumont, R. J., Rourke, I. J., & Gerondakis, S. (1999) · Genes & Development · doi:10.1101/gad.13.4.400 · Cited by 403
De Bosscher, K., Schmitz, M. L., Vanden Berghe, W., Plaisance, S., Fiers, W., & Haegeman, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13504 · Cited by 363
De Bosscher, K., Vanden Berghe, W., Vermeulen, L., Plaisance, S., Boone, E., & Haegeman, G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.3919 · Cited by 335
Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.
Frantz, B., Nordby, E. C., Bren, G., Steffan, N., Paya, C. V., Kincaid, R. L., Tocci, M. J., O'Keefe, S. J., & O'Neill, E. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06329.x · Cited by 334
Bridging the Gap: Composition, Regulation, and Physiological Function of the IκB Kinase Complex
Zandi, E., & Karin, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4547 · Cited by 321
Sheppard, K.-A., Phelps, K. M., Williams, A. J., Thanos, D., Glass, C. K., Rosenfeld, M. G., Gerritsen, M. E., & Collins, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29291 · Cited by 305
Pierce, J. W., Read, M. A., Ding, H., Luscinskas, F. W., & Collins, T. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3961 · Cited by 302
Immunological Aspects of Allergic Asthma
Bochner, B. S., Undem, B. J., & Lichtenstein, L. M. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.001455 · Cited by 294
Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis
Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., & Kaltschmidt, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9409 · Cited by 279
Egan, L. J., Mays, D. C., Huntoon, C. J., Bell, M. P., Pike, M. G., Sandborn, W. J., Lipsky, J. J., & McKean, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26448 · Cited by 217
The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation
Gerondakis, S., Grumont, R., Rourke, I., & Grossmann, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80175-1 · Cited by 191
Lavon, I., Goldberg, I., Amit, S., Landsman, L., Jung, S., Tsuberi, B.-Z., Barshack, I., Kopolovic, J., Galun, E., Bujard, H., et al. (2000) · Nature Medicine · doi:10.1038/75057 · Cited by 165
Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF‐κB activation
Meyer, S., Kohler, N. G., & Joly, A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00930-7 · Cited by 161
FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells.
Venkataraman, L., Burakoff, S. J., & Sen, R. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.3.1091 · Cited by 90
Marienfeld, R. B., Neumann, M., Chuvpilo, S. A., Escher, C., Kneitz, B., Avots, A., Schimpl, A., & Serfling, E. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270703 · Cited by 77
Cited by
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses
Mogensen, T. H. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-08 · Cited by 3,111
Kurutas, E. B. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0186-5 · Cited by 2,152
Dietary phenolics: chemistry, bioavailability and effects on health
Crozier, A., Jaganath, I. B., & Clifford, M. N. (2009) · Natural Product Reports · doi:10.1039/b802662a · Cited by 1,988
Metadata
- Authors
- Yamamoto, Y., & Gaynor, R. B.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-01-15
- Volume
- 107
- Issue
- 2
- Pages
- 135-142
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2086189875
- Cited by
- 1,585
- References
- 48
- FWCI
- 30.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.